Introduction
============

Similar to apoptosis, necroptosis is a novel form of programmed cell death that is considered to be a barrier to tumorigenesis. Tumor necrosis factor (TNF)-induced necroptosis is a canonical model that depends on the TNF receptor, receptor- interacting protein 1/3 (RIP1/3), and mixed lineage kinase-domain like protein (MLKL). When the necroptosis signaling activates, RIP1, RIP3 and MLKL are recruited and phosphorylated in the necrosome successively, and phosphorylation of MLKL is involved in executing necroptosis. RIP3 is a key regulator of TNF-induced necroptosis [@B1], [@B2]. Lack of RIP3 expression is observed in a majority of cancer cell lines due to DNA hypermethylation of the *RIP3* promoter near its transcriptional start site (TSS) [@B3]. Several viral species, such as the Epstein-Barr virus (EBV), herpes simplex virus (HSV), and cytomegalovirus (CMV), are reported by our and other labs to protect cells from necroptosis [@B4], [@B5]. Further research is still needed to shed light on the mechanism by which cancer cells can resist necroptosis induced by virus infection, especially EBV.

EBV is the first characterized oncogenic virus and is implicated in the etiology of nasopharyngeal carcinoma (NPC), a subtype of head and neck squamous cell cancer) [@B6], [@B7]. EBV infection is a recognized epigenetic driver of tumorigenesis. Epigenetic alterations, especially aberrant DNA methylation driven by EBV, are significant in the pathogenesis of EBV-related cancers [@B8]. DNA methylation is the best known epigenetic modification and plays an important role in cancer development. Hypermethylation in the promoter of tumor suppressor genes (TSGs) is a major mechanism of the silencing of TSGs [@B9]. The balance of DNA methylation- demethylation dynamics is maintained by DNA methyltransferases (DNMTs) and ten-eleven translocation methylcytosine dioxygenases (TETs). Any disequilibrium would result in aberrant DNA methylation. The EBV-encoded latent membrane protein 1 (EBV-LMP1, a well-documented onco-protein of EBV) , is reported to induce DNA methylation by up-regulating DNMT1 expression [@B10], [@B11]. Positive LMP1 expression was significantly associated with poorer overall survival in nasopharyngeal carcinoma and non-Hodgkin lymphoma patients [@B12]. We have previously shown that EBV(LMP1) enhances both DNMT1 expression and its DNA methyltransferase activity [@B13]. Thus far, few studies have examined the association between EBV(LMP1) and TETs.

Genetic and epigenetic alterations of enzymes in the tricarboxylic acid (TCA) cycle lead to accumulation of oncometabolites, which in turn participate in the pathogenesis and progression of cancer [@B14]. 2-Hydroxyglutarate (2-HG), succinate, and fumarate are known oncometabolites in the TCA cycle, and their accumulation mainly results from mutations in isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH), and fumarate hydratase (FH), respectively. With a similar structure to α-ketoglutarate (α-KG), they competitively inhibit α-KG-dependent dioxygenases, including TETs and histone lysine demethylases (KDMs), which subsequently cause abnormal epigenetic modifications through DNA or histone methylation [@B15]. Our previous study demonstrated that EBV(LMP1) changes the cellular metabolic profile and plays an important part in cancer cell metabolic reprogramming [@B13], [@B16], [@B17]. Therefore, an interesting question is raised as to whether EBV(LMP1)-associated metabolites are involved in epigenetic modifications.

In this study, we will further examine the pathway of necroptosis resistance induced by EBV infection and the connection between EBV-associated oncometabolites and DNA methylation, in order to better understand the mechanism underlying EBV-related carcinogenesis.

Methods
=======

Cell culture
------------

The human NPC cell lines, HK1, HK1-EBV, C666-1, and C666-1 shLMP1, and the immortalized human nasopharyngeal epithelial cell lines, NP460hTERT and NP460hTERT-EBV, have been described previously [@B13], [@B18]-[@B20]. NPC cell lines were cultured in RPMI-1640 medium (Cat: 11875500, Gibco, Grand Island, NY, USA) supplemented with 10% FBS (Cat: 04-001-1, BI, Kibbutz Beit-Haemek, Israel**)**. NP460hTERT and NP460hTERT-EBV cells were cultured in a 1:1 mixture of Defined Keratinocyte-SFM and EpiLife medium (Cat: 10744019 and MEPI500CA, Gibco). All cells were cultured at 37°C in 5% CO~2~.

Reagents and antibodies
-----------------------

Human TNFα was purchased from Peprotech (Cat: 300-01A, Rocky Hill, NJ, USA). Dimethyl fumarate (DMF), DMSO, and z-VAD-fmk were obtained from Sigma-Aldrich (Cat: V900731, D2650, and C2105, St. Louis, MO, USA). Octyl-α-ketoglutarate (octyl-α-KG) was from Cayman (Cat: 11970, Ann Arbor, MI, USA). Trichostatin A (TSA) and nicotinamide (NAM) were purchased from MCE (Cat: HY-15144 and HY-B0150, Monmouth Juncton, NJ, USA). Smac mimetic and 5-aza-dC were from Selleck (Cat: S7010 and S1200, Houston, TX, USA). TNF-α (T, 100 ng/ml), Smac mimetic (S, 5 μM), and z-VAD-fmk (Z, 20 μM) were used as necroptosis inducers (T/S/Z).

Antibodies used were mouse anti-acetylation (Cat: 66289-1-Ig, Proteintech, Rosemont, IL, USA), mouse anti-β-actin (Cat: A5441, Sigma), rabbit anti-FH (Cat: 11375-1-AP, Proteintech), rabbit anti-LMP1 (Cat: ab78113, Abcam, Cambridge, MA, USA), rabbit anti-MLKL (Cat: M6697, Sigma), rabbit anti-phosphorylated MLKL (Cat: ab187091, Abcam), rabbit anti-RIP3 (Cat: ab56164, Abcam), mouse anti-TET1 (Cat: 61444, Active Motif, Carlsbad, CA, USA).

Immunohistochemistry
--------------------

Nasopharyngitis and NPC tissues were collected from the Department of Pathology at Xiangya Hospital, Central South University, Changsha, China. All patients signed informed consent forms for sample collection. The study was approved by the Medical Ethics Committee of Xiangya Hospital, Central South University (No. 201803134). Immunohistochemical analysis was conducted as described previously [@B21].

Tumorigenicity assay
--------------------

The study was approved by the Medical Ethics Committee (for experimental animals) of Xiangya Hospital, Central South University (No. 201803135). The analysis was performed as described previously [@B22]. 3×10^6^ cells per animal were injected subcutaneously into the flank regions of the 6-week-old female BALB/c-nu mice. The tumors were measured twice a week. The tumor volume was calculated by the following formula: V = 1/6π×length×width^2^. The mice were sacrificed after five weeks, and the weight of xenograft tumors was obtained at the same time.

Western blotting
----------------

Western blot analysis was conducted as previously described [@B13]. Because of the rapid degradation of the LMP1 protein, cells were incubated with 10 mM MG132 (Cat: HY-13259, MCE) for 6 h before harvest to accumulate LMP1 for detection [@B23].

RNA isolation and real-time PCR
-------------------------------

Total mRNA was isolated using the NucleoZOL reagent (Cat: 740404, MACHEREY- NAGEL GmbH & Co. KG, Düren, Germany). The RevertAid First Strand cDNA Synthesis Kit (Cat: K1622, Invitrogen, Carlsbad, CA, USA) was used for reverse transcription. Real-time PCR analysis was performed in triplicate using the SYBR^™^ Green Master Mix (Cat: A25742, Invitrogen) on the ABI7500 Real-Time System (Applied Biosystems).

Cell viability assay
--------------------

Cells were seeded on 96-well plates in replicates of three. A CellTiter 96^®^ AQueous One Solution Cell Proliferation Assay (Cat: G5430, Promega, Madison, WI, USA) was used to evaluate cell viability. Absorbance was measured at a wavelength of 570 nm using the BioTek Elx800 microplate reader.

Cell permeability assay
-----------------------

The cell permeability assay was performed using Sytox Green (Cat: S34860, Invitrogen). Cells were incubated with 30 nM Sytox Green for 20 min in the dark at room temperature, and then visualized with the Leica DMI3000 fluorescence microscope.

DNA methylation
---------------

The genomic sequence near the transcription start site of *RIP3* was retrieved from UCSC Genome Browser (GRCh37/hg19). The CpG island in the *RIP3* promoter was predicted by MethPrimer [@B24]. Methylation-specific PCR (MSP) primers for *RIP3* designed by MethPrimer were as follows: MF: 5\'-GATTGTAGTGAGAACGTCGAG-3\'; MR: 5\'-AAATATCGCCCACTAACCGA-3\'; UF: 5\'-GGATTGTAGTGAGAATGTTGAGT-3\'; UR: 5\'-AAAAATATCACCCACTAACCAACC-3\'. MSP analysis was conducted as previously reported [@B13].

Bisulfite-sequencing PCR (BSP) analysis was performed by TsingKe Biological Technology (Beijing, China). Briefly, 2 μg of genomic DNA was modified by the bisulfate reaction. Bisulfate-treated DNA was amplified with the following primers: F: 5\'-TTATGGTGAGTAGGGAGTGGTATG-3\' and R: 5\'- CATCRTAACCCCACTTCCTATATTAC -3\'. The PCR product was cloned into pUC18, and clones were randomly picked for sequencing. The methylation level of each site is shown as the mean percentage of the total methylation according to sequencing data obtained from 8-10 clones.

DNMT, TET, and FH activity measurement
--------------------------------------

Nuclear proteins were extracted using nuclear and cytoplasmic extraction reagents (Cat: 78835, Thermo Scientific, Waltham, MA, USA). DNMT and TET activities from nuclear extracts were quantified using the EpiQuik™ DNMT activity assay kit and Epigenase™ 5-mC hydroxylase TET activity assay kit (Cat: P3009 and P3086, EpigenTek, Farmingdale, NY, USA), respectively. FH activity was measured by a fumarase activity colorimetric assay kit (Cat: K596, Biovision, Milpitas, CA, USA).

Hydroxymethylated DNA immunoprecipitation (hMeDIP) assay
--------------------------------------------------------

The hMeDIP assay was performed using the EpiQuik™ Hydroxymethylated DNA immunoprecipitation assay kit (Cat: P1038, EpigenTek).

Fumarate, α-KG, succinate, and 2-HG assays
------------------------------------------

α-KG and 2-HG were measured using the alpha-ketoglutarate colorimetric fluorometric assay kit and D-2-hydroxyglutarate colorimetric assay kit (Cat: K677 and K213, Biovision), respectively. Fumarate and succinate were measured using the respective fumarate assay kit and succinate colorimetric assay kits (Cat: MAK060 and MAK184, Sigma).

Database analysis
-----------------

The cBioPortal for the Cancer Genomics Database can be acquired online (<http://www.cbioportal.org/index.do>). The TCGA dataset (N = 530) was used to analyze the prognostic value of RIP3 in head and neck squamous cell carcinoma. The parameters provided in the database for survival analysis were as follows: sex, age, overall survival months, disease-free survival months, survival status, histology grade, pathologic TNM stage, clinical stage, gene expression, and methylation status.

Statistical analysis
--------------------

All statistical analyses were performed using SPSS 17.0 software. The experimental results were statistically evaluated using the Student t test, the Pearson chi-square test, the ANOVA test, COX regression analysis, and Kaplan-Meier analysis. A value of *p* \< 0.05 was considered statistically significant.

Results
=======

*RIP3* promoter hypermethylation indicates a poor prognosis for head and neck squamous cell cancer (HNSCC) patients
-------------------------------------------------------------------------------------------------------------------

Kaplan-Meier curves showed that patients with *RIP3* mRNA negative-expression had a shorter disease-free survival (N=392; median survival time: 53.1 months vs. 71.2 months) and overall survival (N=518; median survival time: 48.2 months vs 60.4 months) compared to those with positive expression in HNSCC patients from the TCGA database (Figure [1](#F1){ref-type="fig"}A). Hypermethylation of the *RIP3* promoter is considered to cause *RIP3*-negative expression [@B3]. We analyzed the relationship between the *RIP3* promoter methylation and mRNA expression, and a significantly negative correlation was observed between the two (Figure [S1](#SM0){ref-type="supplementary-material"}). The survival analysis revealed that patients with *RIP3* promoter methylation had a shorter disease-free survival (N=392; median survival time: 50.0 months vs. a cumulative probability of survival \> 50%) and overall survival (N=518; median survival time: 48.2 months vs. 71.2 months) compared to those with no methylation (Figure [1](#F1){ref-type="fig"}B). The combination of *RIP3* promoter methylation and *RIP3* mRNA expression could stratify patients more accurately (Figure [1](#F1){ref-type="fig"}C). No significant relationship was found between *RIP3* promoter methylation and clinico-pathological parameters (Table [S1](#SM0){ref-type="supplementary-material"}).

Univariate Cox proportional hazards regression analysis showed that advanced T stage, lymph node metastasis, advanced clinical stage, and *RIP3* promoter methylation were significantly correlated with poorer overall survival (Table [1](#T1){ref-type="table"}). Multiple Cox proportional hazards regression analysis indicated that *RIP3* promoter methylation was an independent prognostic factor for HNSCC patients (Table [1](#T1){ref-type="table"}). In addition, the multivariate Cox regression analysis revealed that lymph node metastasis and *RIP3* promoter methylation were independent prognostic factors of poorer disease-free survival for HNSCC patients (Table [2](#T2){ref-type="table"}).

EBV(LMP1) is responsible for RIP3 down-expression in NPC
--------------------------------------------------------

NPC is a subtype of HNSCC. From the Oncomine database, we found that *RIP3* mRNA is significantly down-regulated in NPC tissues (*p* \< 0.001, Figure [S2](#SM0){ref-type="supplementary-material"}). Lack of RIP3 protein expression was detected in NPC tissues, whereas high expression was present in nasopharyngitis tissues (Figure [2](#F2){ref-type="fig"}A).

EBV latent infection plays a crucial role in NPC, thus we determined whether EBV is involved in RIP3 down-regulation. RIP3 expression was examined in EBV- uninfected/infected cells cell lines. Results indicated that *RIP3* mRNA and protein expression were significantly reduced in the EBV-infected immortalized nasopharyngeal epithelial cell line, NP460hTERT-EBV, and the nasopharyngeal carcinoma cell line, HK1-EBV (Figure [2](#F2){ref-type="fig"}B-C). LMP1 is a well-documented onco-protein in the EBV latent infection stage and can be detected in NP460hTERT-EBV and HK1-EBV (Figure [2](#F2){ref-type="fig"}B and S3) cells. Then we examined whether LMP1 is involved in EBV-mediated RIP3 down-regulation. C666-1 cells consistently harbor EBV and express LMP1, while C666-1 cells stably transfected with *LMP1*-shRNA have been established as described previously [@B13], [@B23]. The level of *RIP3* mRNA and protein expression in C666-1 shLMP1 cells was higher than that in C666-1 cells (Figure [2](#F2){ref-type="fig"}B-C and S3). Ectopic expression of LMP1 in HK1 cells decreased the expression of RIP3 (Figure [2](#F2){ref-type="fig"}B-C and S3). This suggested that EBV down-regulated *RIP3* mRNA and protein expression through LMP1 and the regulation was at the transcriptional level.

Next the relationship of LMP1 and RIP3 was analyzed in NPC tissues. The expression was detected by IHC with consecutive sections from the same NPC tissues. Representative photos are shown in Figure [2](#F2){ref-type="fig"}D. Among the 42 NPC specimens, the percentage of LMP1- and RIP3-positive staining was 64.3% (27/42) and 45.2% (19/42), respectively (Figure [2](#F2){ref-type="fig"}E). A significantly negative correlation by the Pearson χ^2^ test was observed between the two proteins (*p* \< 0.05, Table [3](#T3){ref-type="table"}).

Restoring RIP3 expression in EBV(LMP1)-positive cells inhibits xenograft tumor growth in nude mice
--------------------------------------------------------------------------------------------------

To investigate the effect of RIP3 on EBV(LMP1)-mediated tumorigenesis *in vivo,* we performed a xenograft tumor formation assay. C666-1 stably transfected RIP3 (C666-RIP3) cells or empty vector-transfected cells (C666-EV) were injected subcutaneously into nude mice. The average volume and weight of xenograft tumors in mice injected with C666-RIP3 cells were significantly lower compared with C666-EV cells (Figure [2](#F2){ref-type="fig"}F-G and S4A). LMP1 and RIP3 expression in xenograft tumors was examined by IHC (Figure [S4](#SM0){ref-type="supplementary-material"}B).

*RIP3* is silenced by EBV(LMP1) due to hypermethylation of its promoter
-----------------------------------------------------------------------

We considered whether DNA hypermethylation was responsible for EBV(LMP1)-mediated RIP3 down-regulation. BSP analysis showed heavily methylated alleles in EBV(LMP1)-positive cell lines (NP460hTERT-EBV and HK1-EBV), but was barely detectable in EBV(LMP1)-negative cell lines (Figure [3](#F3){ref-type="fig"}A-B). *RIP3* promoter methylation was also examined by MSP analysis**.** DNA hypermethylation occurred in the *RIP3* promoter near its TSS in EBV-infected cell lines (NP460hTERT-EBV, HK1-EBV, and C666-1) and LMP1-positive cells (HK1-LMP1), while the methlylation level was reduced in LMP1-knockdown cells (C666-1 shLMP1, Figure [3](#F3){ref-type="fig"}C).

Then we investigated whether *RIP3* promoter hypermethylation contributed to its low-expression. A hypomethylating agent, 5-aza-dC, was used to treat EBV-infected cell lines. The methylation level of the *RIP3* promoter and *RIP3* mRNA expression were responsive to 5-aza-dC (Figure [3](#F3){ref-type="fig"}D and S5). Moreover, the RIP3 protein was re-expressed in a time-dependent manner with 5-aza-dC treatment in EBV-infected cell lines (Figure [3](#F3){ref-type="fig"}E). The 5-aza-dC treatment also restored RIP3 expression in LMP1-positive cells (Figure [3](#F3){ref-type="fig"}F). These results indicate that EBV(LMP1) induces *RIP3* promoter hypermethylation, which in turn results in the silencing of *RIP3*.

TETs are involved in EBV(LMP1)-mediated *RIP3* promoter hypermethylation
------------------------------------------------------------------------

The dynamic balance of DNA methylation is maintained by methyltransferases (DNMTs) and demethylases (TETs). We previously showed that LMP1 promoted both DNMT1 expression and its enzymatic activity [@B13]. In this study DNMT1 was altered in the same direction in C666-1 cells, but not in NP460hTERT/NP460hTERT-EBV and HK1/HK1-EBV cells (Figure [S6](#SM0){ref-type="supplementary-material"}). Next we examined TETs expression and enzymatic activity. The enzymatic activity of TETs was impaired in EBV(LMP1)-positive cell lines (NP460hTERT-EBV, HK1-EBV, and C666-1), and was restored in LMP1-knockdown cells (C666-1 shLMP1) (Figure [4](#F4){ref-type="fig"}A), while TETs expression was not significantly changed (Figure [S7](#SM0){ref-type="supplementary-material"}). TET enzymes catalyze the oxidation of 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC), which is the first step for active DNA demethylation. Then we used the hMeDIP assay to detect the 5-hmC level in the *RIP3* promoter. As shown in Figure [4](#F4){ref-type="fig"}B, *RIP3* promoter was poorly hydroxymethylated in EBV(LMP1)-positive cell lines, whereas high levels of 5-hmC were observed in LMP1-knockdown cells. These findings suggest that the reduction of TETs enzymatic activity probably results in *RIP3* promoter hypermethylation.

EBV(LMP1) promotes the accumulation of fumarate and reduction of α-KG
---------------------------------------------------------------------

As members of the α-KG-dependent dioxygenase family, TET enzymes require α-KG as a co-substrate to catalyze the conversion of 5-mC to 5-hmC. A few intermediates in the TCA cycle, such as fumarate, succinate, and 2-HG, can competitively inhibit the enzymatic activity of TETs [@B25]. We previously investigated EBV(LMP1)-modulated metabolic changes using a metabolomic approach [@B17]. Fumarate, succinate, 2-HG, and α-KG levels were confirmed in this study. No significant changes of succinate concentration were found between EBV(LMP1)-positive and -negative cell lines (Figure [S8](#SM0){ref-type="supplementary-material"}A). Levels of 2-HG changed less than one fold (significantly) in EBV(LMP1)-positive cell lines (Figure [S8](#SM0){ref-type="supplementary-material"}B). Fumarate levels were appreciably increased in EBV(LMP1)-positive cell lines, and knockdown of LMP1 lessened the level (Figure [4](#F4){ref-type="fig"}C). Moreover, the concentration of α-KG decreased in EBV(LMP1)-positive cell lines (Figure [4](#F4){ref-type="fig"}D). This suggested that EBV(LMP1) significantly promotes the accumulation of fumarate and reduction of α-KG.

EBV(LMP1)-associated metabolite changes regulate TET activity and RIP3 expression
---------------------------------------------------------------------------------

We determined whether fumarate accumulation could affect RIP3 expression. Incubating NP460hTERT or HK1 cells with DMF (a cell-permeable derivative of fumarate) decreased the protein expression of RIP3 in a time-dependent manner (Figure [5](#F5){ref-type="fig"}A). Promoter methylation and mRNA expression levels of *RIP3* were also depressed with DMF treatment (Figure [5](#F5){ref-type="fig"}B-D). Fumatate is a competitive inhibitor of TETs, so 5mC-hydroxylase activity was examined. As shown in Figure [5](#F5){ref-type="fig"}C-D, DMF treatment inhibited TET enzymatic activity and the 5-hmC levels in the *RIP3* promoter were also lower in DMF-treated cells (Figure [5](#F5){ref-type="fig"}C-D).

Next, we determined whether raising the α-KG concentration could restore EBV(LMP1)-induced *RIP3* silencing. Cell-permeable octyl-α-KG was used a supplement of α-KG [@B26]. With octyl-α-KG treatment, *RIP3* expression, TET activity, and 5-hmC levels in the *RIP3* promoter were increased in EBV(LMP1)-positive cells (Figure [5](#F5){ref-type="fig"}E-F).

These observations indicate that EBV(LMP1)-associated fumarate accumulation and α-KG reduction cause *RIP3* silencing due to TET activity-dependent hypermethylation.

EBV(LMP1) suppresses FH activity
--------------------------------

Loss-of-function mutation of *FH* results in accumulation of its substrate fumarate [@B14]. As shown in Figure [6](#F6){ref-type="fig"}A, FH activity decreased in EBV(LMP1)-positive cell lines, and increased in LMP1-knockdown cells. However, no mutations were found in 56 NPC tissues by searching the cBioPortal for Cancer Genomics Database for the mutation status of *FH* and other frequently mutated genes involved in the TCA cycle (Figure [S9](#SM0){ref-type="supplementary-material"}). Western blot analysis revealed no significant alteration in the FH protein expression (Figure [6](#F6){ref-type="fig"}B).This demonstrated that the reduction of FH activity is responsible for fumarate accumulation, instead of *FH* mutations or its abnormal expression.

Most of the metabolic enzymes in the TCA cycle, including FH, are acetylated, and their enzyme activity or protein stability relies on lysine acetylation [@B27], [@B28]. We determined whether the acetylation of FH was affected by EBV(LMP1). Figure [6](#F6){ref-type="fig"}B shows that acetylation of endogenous FH decreased in EBV(LMP1)-positive cell lines and increased in LMP1-knockdown cells. To determine the effect of acetylation on FH enzymatic activity, we treated 460hTERT-EBV/ HK1-EBV cells with TSA (a class I, II, IV HDAC inhibitor) and NAM (a NAD^+^-dependent class III SIRT inhibitor), respectively. TSA treatment increased endogenous FH acetylation and activity (Figure [6](#F6){ref-type="fig"}C-D). This suggested that acetylation may play a role in EBV(LMP1)-mediated reduction of FH activity.

Fumarate inhibits TNF-induced necroptosis
-----------------------------------------

RIP3 is a key regulator of TNF-induced necroptosis [@B1], [@B2]. We next investigated whether fumarate accumulation might play a role in TNF-induced necroptosis. Cell viability assay results showed that the necroptosis inducer (T/S/Z) led to massive cell death and DMF pre-treatment restored cell viability (Figure [7](#F7){ref-type="fig"}A). MLKL is a key RIP3 downstream component and its phosphorylation is indispensable for TNF-induced necroptosis [@B29]. Western blot analysis revealed that T/S/Z treatment induced the phosphorylation of MLKL, while the phosphorylation was hardly observed in the DMF pre-treated group (Figure [7](#F7){ref-type="fig"}B). The rupture of the plasma membrane is a remarkable feature of necroptosis [@B30], and therefore we examined cell permeability using Sytox Green staining. Our results showed that T/S/Z treatment increased the Sytox Green fluorescence signal, while the staining was suppressed by DMF pre-treatment (Figure [7](#F7){ref-type="fig"}C). Overall, changes in EBV(LMP1)-associated metabolites inhibit TNF-induced necroptosis (Figure [8](#F8){ref-type="fig"}).

Discussion
==========

Necroptosis is considered to be a defense against viral infection. Several viruses can escape from necroptosis by encoding inhibitors, such as vIRA/M45 (MCMV), ICP6 (HSV-1), and ICP10 (HSV-2) [@B4]. We have shown that EBV and EBV-encoded LMP1 could inhibit necroptosis through post-translational modification of RIP1/3 [@B5], [@B31]. In this study, we revealed a novel mechanism of necroptosis resistance by silencing *RIP3* expression in a methylation-dependent manner in cells with EBV infection (Figure [8](#F8){ref-type="fig"}).

*RIP3* is a critical regulator of necroptosis, which is considered to be a TSG. Lack of RIP3 expression could reduce the sensitivity of cells to necroptosis stimuli, and then promote cell viability and tumorigenesis. RIP3 is reported to be down-regulated in colorectal cancer, breast cancer, and esophageal squamous cell carcinoma, and the low expression of RIP3 is associated with a poor prognosis [@B3], [@B32], [@B33]. In this study, we showed that RIP3 s expressed at low levels in NPC tissues. Not only negative RIP3 protein expression, but *RIP3* promoter methylation was correlated with a shorter disease-free and overall survival in HNSCC. Furthermore, *RIP3* promoter hypermethylation was an independent prognostic factor for poor clinical outcome. Therefore, *RIP3* promoter methylation seems to be a valuable factor in cancer diagnosis and treatment.

DNA methylation is considered to be a reversible progression with the balance maintained by DNMTs and TETs. DNMT1 is the most abundant DNMT in mammalian cells and it maintains methylation status during cell replication [@B34]. Over-expression of DNMT1 disrupts the DNA methylation-demethylation balance, which results in promoter hypermethylation and silencing of the expression of many TSGs [@B35]. Lack of RIP3 expression has been observed in a variety of cancer cell lines and breast cancer tissues, mainly because of DNMT1-dependent hypermethylation [@B3], [@B36], [@B37]. Unlike DNMTs and DNA methylation, TETs and DNA demethylation have not been well studied. As another regulator of the balance, TETs (including TET1, TET2, and TET3) oxidize 5-mC to 5-hmC and other oxidation products, thereby mediating active DNA demethylation. Decreased expression/ or activity of TETs and low levels of 5-hmC are hallmarks of various cancers [@B38], [@B39]. EBV infection is an epigenetic driver. EBV(LMP1) is known to upset the balance by increasing DNMT1 expression and activity [@B10], [@B11], [@B13]. Surprisingly, data regarding the relationship between EBV infection and TETs are limited. Here we demonstrated that EBV(LMP1) reduced the activity of TETs and consequently led to *RIP3* promoter hypermethylation. Altogether, LMP1 could regulate DNA methylation by two axis: LMP1-DNMT1 and LMP1-TETs in various cell lines, because of tumor heterogeneity of nasopharyngeal carcinoma.

Fumarate, regarded as an oncometabolite, is reported to mediate DNA and histone demethylation by preventing α-KG-dependent dioxygenase, TETs and KDMs, activities [@B40], [@B41]. In multiple cancers, fumarate accumulation is caused by mutation of *FH* [@B14], [@B42]. Loss-of-function mutation of *FH* results in loss of 5-hmC [@B43], [@B44]. Few studies have focused on fumarate hydratase activity independent of mutation. Our data showed that FH protein acetylation, instead of *FH* mutation or its abnormal expression, may lead to its reduction in activity and fumarate accumulation, which might be a reason for weakened TETs enzymatic activity and *RIP3* silencing. Interestingly, fumarate hydratase has been identified in the RIP3 complex [@B2]. Therefore, future studies need to explore the crosstalk between RIP3 and FH.

Metabolic reprogramming is a hallmark of viral oncogenesis [@B45]. We previously reported that EBV(LMP1) expression and activity resulted in various metabolite changes and high levels of glycolysis [@B13], [@B17]. EBV(LMP1) expression resulted in the accumulation of fumarate and reduction of α-KG, which silenced *RIP3* expression in a methylation-dependent manner. In this study, EBV(LMP1) linked metabolic changes with epigenetic modifications. Our previous study revealed the mechanism as to how the EBV(LMP1)-mediated signaling axes led to metabolism reprogramming [@B13], [@B17], [@B46]. Here we showed that EBV(LMP1)-associated metabolite changes inhibited necroptosis signaling and promoted oncogenesis, which would enrich the EBV(LMP1) oncogenic signaling network.

In conclusion, our results demonstrate a novel pathway in which EBV(LMP1)-associated oncometabolites by DNA methylation led to necroptosis resistance, and also shed light on the mechanism underlying EBV-related carcinogenesis, which may provide new options for cancer diagnosis and therapy.
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HNSCC

:   head and neck squamous cell cancer

HSV

:   herpes simplex virus

IDH

:   isocitrate dehydrogenase

KDM

:   histone lysine demethylase

MSP

:   methlyation-specific PCR

MLKL

:   mixed lineage kinase-domain like protein

NP

:   nasopharyngitis

NPC

:   nasopharyngeal carcinoma

RIP1/3

:   receptor-interacting protein 1/3

SDH

:   succinate dehydrogenase

TET

:   ten-eleven translocation methylcytosine dioxygenase

TNF

:   tumor necrosis factor

TSG

:   tumor suppressor gene

TSS

:   transcriptional start site

![**Kaplan-Meier analysis according to *RIP3* promoter methylation and mRNA expression status in HNSCC patients.** A, Disease-free survival (left) and overall survival (right) analysis according to *RIP3* mRNA expression. HNSCC patients were divided into two groups: good prognosis (positive expression of *RIP3* mRNA) and poor prognosis (negative expression of *RIP3* mRNA; "-", negative; "+", positive). B, Disease-free survival (left) and overall survival (right) analysis according to *RIP3* promoter methylation. HNSCC patients were divided into two groups: good prognosis (unmethylated *RIP3* promoter) and poor prognosis (methylated *RIP3* promoter). U, unmethylated; M, methylated. C, Disease-free survival (left) and overall survival (right) analysis according to the combination of *RIP3* promoter methylation and mRNA expression. The combination could stratify HNSCC patients more accurately than just one factor.](thnov09p2424g001){#F1}

![**RIP3 expression is negatively associated with EBV(LMP1), and restoring RIP3 expression inhibits EBV(LMP1)-mediated tumorigenesis.** A, Representative IHC photos for the expression of RIP3. Compared with NP tissues, RIP3 is expressed at low levels in NPC tissues. NP: nasopharyngitis; NPC: nasopharyngeal carcinoma. B, RIP3 protein expression is down-regulated in EBV(LMP1)-positive cells detected by Western blot analysis. EBV- uninfected/infected cells: NP460hTERT/ NP460hTERT-EBV (immortalized human nasopharyngeal epithelial cell), HK1/ HK1-EBV (differentiated NPC cells), C666-1 (undifferentiated NPC cells harboring EBV). LMP1-associated cells: HK1-Vec/ HK1-LMP1 (HK1 cells were transfected with LMP1- overexpression vector), C666-1/ C666-1 shLMP1 (C666-1 cells stably transfected with shLMP1). C, *RIP3* mRNA expression is down-regulated in EBV(LMP1)-positive cells detected by RT-PCR (columns = mean; bars = S.D.; n = 3; \*\*, *p* \< 0.01). D, Representative IHC photos for the expression of LMP1 and RIP3 in consecutive sections of NPC tissues. E, RIP3 expression is calculated according to LMP1 expression in NPC tissues. F, Tumor growth curves of C666-1 xenografts in groups indicated. Data are expressed as mean values ± S.D. (n = 5; \*\*\**p* \< 0.001). G, Tumor weight was measured at the end of the experiment. Data are expressed as mean values ± S.D. (n = 5; \*\*\*p \< 0.001).](thnov09p2424g002){#F2}

![**RIP3 is silenced by methylation in EBV(LMP1)-positive cell lines.** A, Methylation levels of CpG sites in the *RIP3* promoter near its TSS (+164 to +404) in NP460hTERT-EBV cells are higher than those in NP460hTERT cells as detected by BSP (left and middle). The results are statistically significant (right). Dot, the mean methylation level of a single CpG island (\*\*\*, *p* \< 0.001). B, Methylation levels of *RIP3* promoter are significantly higher in HK1-EBV cells compared to HK1 cells (the same as above). C, Promoter methylation of *RIP3* in EBV(LMP1)-positive/negative cell lines validated by MSP (M, methylated; U, unmethylated.). D, With 5-aza-dC (10 μM, 4 days) treatment, methylation level of *RIP3* promoter is down-regulated as detected by MSP (M, methylated; U, unmethylated). E, RIP3 protein is restored in a time-dependent manner in EBV-infected cells treated with 5-aza-dC (10 μM) as detected by Western blotting. F, RIP3 protein is restored in LMP1-positive cells treated with 5-aza-dC (10 μM, 4 days) as detected by Western blotting.](thnov09p2424g003){#F3}

![**EBV(LMP1) regulates TET enzymatic activity and metabolic changes.** A, TET 5mC-hydroxylase activity is down-regulated in EBV-infected cells (left and middle). Knockdown of LMP1 expression in C666-1 restored TET activity (right; columns = mean; bars = S.D.; n = 3; \*\*, *p* \< 0.01). B, Hydroxymethylated DNA immunoprecipitation (hMeDIP) assays to determine 5-hmC levels in the *RIP3* promoter. The 5-hmC level is reduced in EBV-infected cells (left and middle) and knockdown of LMP1 expression in C666-1 elevates the 5-hmC level (right; columns = mean; bars = S.D.; n = 3; \*\*, *p* \< 0.01). C, Fumarate accumulates in EBV-infected cells (left and middle). The level of fumarate is decreased in LMP1-knockdown cells (right; columns = mean; bars = S.D.; n = 3; \*\*, *p* \< 0.01). D, The level of α-KG is decreased in EBV-infected cells (left and middle) and the level is increased in LMP1-knockdown cells (right; columns = mean; bars = S.D.; n = 3; \*\*, *p* \< 0.01).](thnov09p2424g004){#F4}

![**EBV(LMP1)-associated metabolite changes regulate TET activity and RIP3 expression.** A, Western blot analysis of RIP3 expression in NP460hTERT (left) and HK1 (right) cells treated with DMF (50 μM) for the indicated times. Treatment wtih DMF decreases the protein expression of RIP3 in a time-dependent manner. B, DMF (50 μM, 4 days) treatment increases methylation levels of the *RIP3* promoter as detected by MSP (M, methylated; U, unmethylated). C-D, NP460hTERT (C) and HK1 (D) cells were treated with DMSO or DMF (50 μM, 4 days). The mRNA expression of *RIP3* (left), TET 5mC-hydroxylase activity levels (middle), and 5-hmC levels of *RIP3* promoter (right) are decreased in the DMF-treated group (columns = mean; bars = S.D.; n = 3; \*\*, *p* \< 0.01). E-F, NP460hTERT-EBV (E) and HK1-EBV (F) cells were treated with DMSO or octyl-α-KG (1 mM, 24 hours). The mRNA expression of *RIP3* (left), TET 5mC-hydroxylase activity levels (middle), and 5-hmC levels of *RIP3* promoter (right) are increased in the α-KG -treated group (columns = means; bars = S.D.; n = 3; \*, *p* \< 0.05; \*\*, *p* \< 0.01).](thnov09p2424g005){#F5}

![**EBV(LMP1) inhibits FH activity.** A, FH activity declines in EBV-infected cells (left and middle) and the activity is increased in LMP1-knockdown cells (right; columns = mean; bars = S.D.; n = 3; \*\*, *p* \< 0.01). B, Endogenous FH was immunoprecipitated (IP) and probed with FH and acetyl-Lys (Ac-K) antibodies. The whole cell extract was used as input. C-D, Cells were treated with 5 μM TSA or 5 mM NAM for 16 hours. The endogenous FH was immunoprecipitated and analyzed by Western blotting (C). FH activity were also detected (D; columns = means; bars = S.D.; n = 3; \*\*, *p* \< 0.01).](thnov09p2424g006){#F6}

![**Fumarate inhibits T/S/Z-induced necroptosis.** NP460hTERT and HK1 cells were untreated or pretreated with DMF (50 μM, 4 days) followed by treatment with TNF-α (T, 100ng/ml)/ Smac mimetic (S, 5 μM)/ z-VAD-fmk (Z, 20 μM) for 24 (NP460hTERT) or 48 h (HK1). A, Cell viability was determined by MTS (columns = means; bars = S.D.; n = 3; \*\*, *p* \< 0.01. B, Western blot analysis of RIP3, p-MLKL and MLKL expression. C, The integrity of cellular membrane was determined by Sytox Green fluorescence staining (left). The results are statistically significant (right; columns = means; bars = S.D.; n = 3; \*, *p* \< 0.05; \*\*, *p* \< 0.01).](thnov09p2424g007){#F7}

![**A schematic for EBV-induced epigenetic reprogramming of RIP3.** The metabolic reprogramming caused by EBV(LMP1) expression inhibits necroptosis signaling through the hypermethylation of the *RIP3* promoter, which sheds light on the mechanism underlying EBV-related carcinogenesis.](thnov09p2424g008){#F8}

###### 

Univariate and multivariate COX regression analysis of disease-free survival of HNSCC patients

  Variable                       Univariate analysis                 Multivariate analysis                            
  ------------------------------ --------------------- ------------- ----------------------- -- ------- ------------- ----------
  **Age** (≥61 vs \<61)          1.088                 0.785-1.507   0.613                                            
  **Sex** (Male vs Female)       1.461                 0.976-2.186   0.0656                                           
  **Grade** (G3/G4 vs G1/G2)     0.722                 0.478-1.089   0.120                                            
  **pT** (T3/T4 vs T1/T2)        1.511                 1.046-2.183   0.0279\*                   1.351   0.851-2.144   0.202
  **pN** (N1/N2/N3 vs N0)        1.668                 1.149-2.421   0.00717\*                  1.488   0.996-2.222   0.0523\*
  **Stage** (IV vs I/II/III)     1.531                 1.077-2.176   0.0177\*                   1.294   0.828-2.022   0.258
  ***RIP3* promoter** (M vs U)   1.497                 1.072-2.092   0.0179\*                   1.566   1.075-2.282   0.0193\*

HR, hazard ratio; CI, confidence interval; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; G4, Undifferentiated; pT, pathologic T stage; pN, lymph node metastases; M, methylated; U, unmethylated; \*, significant difference.

###### 

Univariate and multivariate COX regression analysis of overall survival of HNSCC patients

  Variable                       Univariate analysis                 Multivariate analysis                            
  ------------------------------ --------------------- ------------- ----------------------- -- ------- ------------- ---------------
  **Age** (≥61 vs \<61)          1.259                 0.964-1.644   0.0914                                           
  **Sex** (Male vs Female)       1.156                 0.851-1.570   0.353                                            
  **Grade** (G3/G4 vs G1/G2)     0.775                 0.555-1.083   0.136                                            
  **pT** (T3/T4 vs T1/T2)        1.252                 0.942-1.666   0.122                                            
  **pN** (N1/N2/N3 vs N0)        1.789                 1.297-2.468   3.96×10^-4^\*              1.882   1.355-2.612   1.59×10^-4^\*
  **Stage** (IV vs I/II/III)     1.103                 0.842-1.445   0.475                                            
  ***RIP3* promoter** (M vs U)   1.354                 1.035-1.772   0.0271\*                   1.384   1.018-1.882   0.0381\*

HR, hazard ratio; CI, confidence interval; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; G4, Undifferentiated; pT, pathologic T stage; pN, lymph node metastases; M, methylated; U, unmethylated; \*, significant difference.

###### 

RIP3 expression negatively correlates with LMP1 expression in NPC

  RIP3        LMP1     Total    
  ----------- -------- -------- --------
  Negative    5        18       **23**
  Positive    10       9        **19**
  **Total**   **15**   **27**   **42**

Pearson Chi-Square Test,*P* = 0.038
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